

## Real-world Evidence Study

Year/s	Methods	Participants	Key Findings	Reference
2021–2022	A de-identified aggregate data analysis of the initial 124 Canvas Dx prescriptions fulfilled post-market authorization.	<p>The first 124 real-world Canvas Dx users</p> <p>Prescriptions were generated from 15 states. Children had a median age of 39.6 months, were 27.4% female, and had a 51.6% autism prevalence rate.</p>	Compared to the clinical reference standard, Canvas Dx had a NPV of 95.2% (20/21, 95% CI [76.2%, 99.9%]) and PPV of 94.4% (51/54, 95% CI [84.6%, 98.8%]) with 60.5% (75/124, 95% CI [51.3%, 69.1%]) receiving a determinate (positive or negative for autism) result. The median age of children who received a positive output was 35.5 months: this is over 1 year earlier than the current median age of autism diagnosis in the U.S.	Taraman, S., et al. Exploring the Real-World Performance of an Artificial Intelligence-Based Diagnostic Device for ASD: An Aggregate Analysis of Early Canvas Dx Prescription and Output Data. <i>Journal of the American Academy of Child &amp; Adolescent Psychiatry</i> Volume 62, Number 10S, October 2023.